Journal profile
Oncology Advances
ISSN 2996-3427 · Xia & He Publishing Inc. · USA · Quarterly · Founded 2023
Oncology Advances: fully open access; APC about USD 680; review about 33 days (submission to first decision, publisher); community-reported acceptance: 63%; 20 articles in 2025.
Scope
Aims, scope and focus
Oncology Advances is published by Xia & He Publishing Inc.. By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Nanoparticle-Based Drug Delivery and Immunotherapy and Immune Responses, together about 28% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Oncology Advances is dedicated to improving the diagnosis and treatment of human malignancies, advancing the understanding of molecular mechanisms underlying oncogenesis, and promoting translation from bench to bedside of oncological sciences. The aim of Oncology Advances is to publish peer-reviewed, high-quality articles in all aspects of translational and clinical studies on human cancers, as well as cutting-edge preclinical and clinical research of novel cancer therapies.
From the journal's Aims & Scope
Editor-in-chief Ruiwen ZhangPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine16%
- Nanoparticle-Based Drug DeliveryMaterials Science6.7%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.3%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.3%
- Prostate Cancer Diagnosis and TreatmentMedicine4%
- Glioma Diagnosis and TreatmentMedicine4%
- Cervical Cancer and HPV ResearchMedicine4%
- Acute Myeloid Leukemia ResearchMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 3OpenAlex ·
- i10-index
- 0OpenAlex ·
- 2-year mean citedness
- 0.76OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 62 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 9 | 9 | 33 |
| 2025 | 20 | 20 | 16 |
| 2024 | 26 | 26 | 3 |
| 2023 | 7 | 7 | 0 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average acceptance (community reports)
- 63%LetPub ·
- Acceptance rate (publisher)
- 59%Publisher website ·
- Submission to first decision
- 33 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessLetPub
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 680 / USD 450 | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Reference style
- Vancouver
- Suggested reviewers
- Optional
Article types accepted13, with length limits
- case reportScope: Case Report manuscripts should describe an individual patient or series of patients (normally less than three) that presented with an unexpected or rare …Length not stated
- commentaryPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…Length not stated
- editorialPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…main text ≤ 1,000 words · figures and tables ≤ 1 · references ≤ 10
- letterPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…main text ≤ 1,500 words
- letter to the editorPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…main text ≤ 800 words · figures and tables ≤ 1 · references ≤ 10
- meta-analysisPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…Length not stated
- mini-reviewMini-review Unstructured; No more than 250 words ~ 2 ~ 3000 words; Structured as Introduction, main body, and Conclusions ~ 70Length not stated
- opinionPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…main text ≤ 1,500 words
- original articleScope: Original research manuscripts should describe experimental and/or clinical studies in oncological sciences and clinical oncology, including exploratory a…main text ≤ 5,000 words · figures and tables ≤ 8 · references ≤ 50
- research letterResearch Letter ~ 3 ~ 1500 words; Unstructured ~ 20Length not stated
- reviewPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…main text ≤ 3,000 words · figures and tables ≤ 10 · references ≤ 300
- systematic reviewScope: A systematic review paper, as defined by the Cochrane Collaboration, is a review of a clearly formulated question that uses explicit, systematic methods …main text ≤ 5,000 words · figures and tables ≤ 8 · references ≤ 70
- systematic review and meta-analysisSystematic Review and Meta-analysis Structured with Background and objectives, Methods, Results, and Conclusions; No more than 250 words ~ 8 ~ 5000 words; Struc…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints, Self-archiving, Trial registration / reporting guidelines
- AI use Use of AI Tools by Reviewers
Manuscripts under review are confidential. Reviewers must not upload unpublished manuscripts, figures, tables, supplementary files, review reports, or any confidential manuscript-related information to public AI platforms.
Source ↗Publisher website ·- Authorship Author Contributions
Copyright retained with authors Model summary
The Authors’ Contributions should be provided in paragraph form following the authors’ names and affiliations and corresponding author(s)’ information. The manner in which each author was involved with the study or preparation of the manuscript is listed with the author’s name (shown as initials, within parentheses). Contributions that are acceptable for inclusion as an author are: study design, p…
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
All authors must check the ICMJE’s unified disclosure form. Each author should check the form to disclose any potential conflict of interest and is responsible for the accuracy and completeness of the provided information. The ICMJE’s form could be downloaded here.
Source ↗Publisher website ·- Data availability Data Sharing Statement
A Data Sharing Statement is required for research articles through which readers will know how to access the shared data. Sample wording: The [TYPE, such as technical appendix, statistical code, or dataset] data used to support the findings of this study have been deposited in the [NAME] repository ([DOI or other persistent identifier]); The [TYPE] data used to support the findings of this study a…
Source ↗Publisher website ·- Publication ethics
Follows COPE and ICMJE ethics recommendations Model summary
Please ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE), as well as the general article requirements.
Source ↗Publisher website ·- License & copyright Copyright
The copyright on all published articles will be retained with the authors unless stated otherwise. Authors grant Oncology Advances the sole, worldwide, and exclusive right to publish (i.e., print, publish, sell, and otherwise commercially exploit), reproduce, display, and store the published articles.
Source ↗Publisher website ·- Open access Open Access
Open access under CC BY-NC 4.0 license Model summary
Oncology Advances adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are su…
Source ↗Publisher website ·- Peer review Peer Review & Editorial Process
The objective of the peer review process is to ensure the integrity and transparency of the research objectives, data, and conclusions.Editorial ProcessAll articles, solicited and unsolicited, that are submitted to Oncology Advances will be subject to the following single blind peer review process, meaning that the author does not know the identity of the reviewer, but the reviewer knows the ident…
Source ↗Publisher website ·- Plagiarism Types of Plagiarism
Plagiarism screening via Crossref Similarity Check Model summary
Plagiarism is defined by the Oncology Advances as the use of information, including textual descriptions, figures/tables and data, from a previously published document without proper citation or reference to the original source. All submitted manuscripts will be checked using plagiarism detection software (Crossref Similarity Check).
Source ↗Publisher website ·- Preprints Preprint version
A preprint is the version of an article before peer-review. Authors are not requested to remove a preprint from a not-for-profit preprint server before submission. Upon acceptance, we recommend including an acknowledgement of acceptance on the first page, as follows:
Source ↗Publisher website ·- Self-archiving Self-archiving Policy
Self-archiving permitted without embargo Model summary
Authors of articles published in Oncology Advances are permitted to self-archive the preprint version of the article at any time, and may self-archive the postprint and published version without embargo.
Source ↗Publisher website ·- Trial registration / reporting guidelines Study Reporting Guidelines
To enhance the quality and transparency of health research, Oncology Advances requires all investigators to prepare articles according to appropriate EQUATOR research reporting guidelines. Each submission of an original article/systematic review/meta-analysis/case report/study protocol should be accompanied by an appropriate checklist as listed below. Authors can find more guidelines at EQUATOR an…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Xia & He Publishing Inc.
- Country or region
- USA
- Language
- English
- Frequency
- Quarterly
- Founded
- 2023
- ISSN
- 2996-3427
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Oncology Advances
How long does peer review take at Oncology Advances?
The publisher reports about 33 days (submission to first decision); first decisions include desk rejections; the community-reported acceptance is “63%”; the journal's website gives an acceptance rate of 59%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Oncology Advances?
According to the journal's author guidelines: Reference style: Vancouver; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Is Oncology Advances open access, and what is the APC?
Oncology Advances is a fully open-access journal. APC about USD 680.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .